scientific reports

OPEN

Check for updates

A systematic review and meta-analysis of the effect of phonophoresis on patients with knee osteoarthritis

Fu-An Yang¹, Hung-Lun Chen¹, Chih-Wei Peng^{2,3}, Tsan-Hon Liou^{4,5}, Reuben Escorpizo^{6,7} & Hung-Chou Chen^{4,5,8}⊠

This systematic review and meta-analysis investigated the effect of phonophoresis when various gel types were used. Medline (using PubMed), EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were used to search for relevant studies from the date of their inception to June 28, 2021. We included studies that were randomized controlled trials (RCTs), included patients with a diagnosis of knee osteoarthritis, included treatment with either phonophoresis or therapeutic ultrasound with placebo gel, and reported clinical and functional outcomes. Continuous variables are expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Statistical analysis was performed using RevMan 5.3 software. We initially retrieved 2176 studies and finally analyzed nine RCTs including 423 patients. The intervention group significantly outperformed the control group in pain scores with NSAID gel (SMD = -0.53, 95% CI [-1.02, -0.05], $l^2 = 73\%$) and in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) function score with corticosteroid gel (SMD = -0.96, 95% CI [-1.47, -0.44], $l^2 = 20\%$). Phonophoresis alleviated pain and improved functional performance. Because of some limitations of this study, additional high-quality, large-scale RCTs are required to confirm the benefits.

Knee osteoarthritis is characterized by breakdown of the articular cartilage over time^{1,2}. Although cartilage breakdown is the major disease characteristic, osteoarthritis affects all joint tissues, including the synovial membrane, which is usually associated with increased pain and joint dysfunction^{2,3}. Common clinical symptoms include knee pain with gradual onset and that worsens with activity, knee stiffness and swelling, pain after prolonged sitting or resting, and pain that worsens over time⁴. Some studies have reported that approximately 13% of women and 10% of men aged 60 years or older have symptomatic knee osteoarthritis^{5,6}.

Treatment initially involves nonsurgical modalities and progresses to surgical treatment once nonsurgical methods are no longer effective⁴. These interventions do not alter the disease process but may substantially reduce pain and disability^{7,8}. Self-management programs, muscle strengthening, low-impact aerobic exercises, neuromuscular therapy, and physical activity are recommended for patients with knee osteoarthritis^{9–12}. Oral pharmacological agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are effective in the treatment of knee osteoarthritis^{13–15}. However, oral anti-inflammatory drugs may increase the risks of gastrointestinal, renal, and other systemic toxicities. Topical gels are an alternative treatment option with fewer complications compared with oral anti-inflammatory drugs^{16–18}.

Ultrasound, as a treatment modality, has been studied for many decades¹⁹. Ultrasound exerts a therapeutic effect through the absorption of mechanical energy and the production of heat in tissues²⁰. Phonophoresis involves the use of ultrasound to deliver therapeutic drugs by absorption and permeation of the skin²¹.

¹School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. ²School of Gerontology Health Management, College of Nursing, Taipei Medical University, Taipei, Taiwan. ³School of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan. ⁴Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei Medical University, No. 291 Zhongzheng Road, Zhonghe District, New Taipei City 235, Taiwan. ⁵Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. ⁶Department of Rehabilitation and Movement Science, College of Nursing and Health Sciences, University of Vermont, Burlington, VT, USA. ⁷Swiss Paraplegic Research, Nottwil, Switzerland. ⁸Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan. [⊠]email: 10462@s.tmu.edu.tw Phonophoresis with an anti-inflammatory gel has been reported to alleviate pain and inflammation in many musculoskeletal conditions^{22–25}. Despite the wide use of phonophoresis, scientific evidence supporting its use is insufficient, especially with regard to symptomatic knee osteoarthritis. Wu et al. conducted a systematic review and meta-analysis comparing the effects of therapeutic ultrasound with those of sham ultrasound on knee osteoarthritis²⁶. A subgroup analysis indicated that the phonophoresis ultrasound group reported less pain (measured using the visual analog scale [VAS]) than did the conventional nondrug ultrasound group²⁶. No significant differences in functional performance (determined on the basis of Western Ontario and McMaster Universities Arthritis Index [WOMAC] score) were observed between the groups²⁶. However, only three randomized controlled trials (RCTs) were included in the study to compare the effect of phonophoresis with that of nondrug therapeutic ultrasound. Moreover, according to our electronic database search, more RCTs have been published recently. Thus, this study investigated the effect of phonophoresis for various gel types and compared these effects against those of a placebo (nondrug) gel; these gels were used in therapeutic ultrasound for treating knee osteoarthritis.

Method

This review was performed in accordance with the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions²⁷ and is reported following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses²⁸. This systematic review was registered in the International Prospective Register of Systematic Reviews database under the number CRD42021266126 on August 6, 2021.

Eligibility criteria. We included studies that (1) were RCTs; (2) included patients with a diagnosis of knee osteoarthritis; (3) involved treatment with phonophoresis (with an NSAID, corticosteroid, Chinese herbal gel, or other gel) as the intervention; (4) involved therapeutic ultrasound with a placebo (nondrug) gel as the control treatment; and (5) reported clinical outcomes including pain scores (measured using the VAS) and functional performance (assessed on the basis of WOMAC function score, range of motion, and a walk test). We excluded articles that were protocols, non-peer-reviewed articles, conference papers, and letters to the editor. No language restriction was applied in our search strategy.

Literature search. We searched electronic databases, namely Medline (using PubMed), EMBASE, and CENTRAL. In our search strategy, we included terms related to both phonophoresis and knee osteoarthritis and their synonyms (the search strategies are presented in the Supplementary Appendix). If available, RCTs were identified using the refined search function of the databases. Additional articles were identified by manually searching the reference lists of relevant articles. The databases were searched from their inception to June 28, 2021.

Study selection. Only RCTs that compared the effects of phonophoresis with those of nondrug therapeutic ultrasound on pain and physical function in patients with knee osteoarthritis were included. Titles and abstracts were screened to select relevant articles. Two reviewers independently evaluated the eligibility of all titles and abstracts, and disagreements were resolved through discussion. A third reviewer adjudicated any disagreement that could not be resolved through discussion. Subsequently, the full texts of remaining articles were read in detail to determine the eligibility of the articles.

Data extraction. Two authors extracted data from each study by using a structured form, and the characteristics of all eligible studies are summarized in a table. The following data were extracted: (1) basic information of qualifying studies (first author and publication date); (2) demographic, clinical, and treatment characteristics (e.g., number and mean age of patients in the control and treatment groups); (3) therapeutic ultrasound parameters (mode, frequency, intensity, and duration); (4) content of the gel used in phonophoresis; (5) follow-up period; and (6) outcome measures. Moreover, the means and standard deviations (SDs) of outcome measurements before and after treatment for the experimental and control groups were extracted. If crucial data could not be extracted from an article, we sent an email to the corresponding author, requesting the data.

Outcome measurements. The outcome measurements of this study were pain score, WOMAC function score, range of motion, walk test score, and adverse events. The pain scores were VAS scores²⁹. Higher VAS scores indicate a higher intensity of pain. The WOMAC function score is obtained from a self-administered question-naire widely used for evaluating hip and knee osteoarthritis³⁰. Higher WOMAC function scores indicate higher pain intensity, greater stiffness, and poorer physical function. Range of motion is the range through which a joint can be moved³¹. The walk tests included in this study were the 6-min walk test, timed up and go test, 15-min walk test, and 20-min walk test^{32,33}.

Risk of bias assessment. Risk of bias was examined using the RoB 2 tool, a revision of the Cochrane riskof-bias tool for RCTs, which is widely used for assessing the quality of RCTs³⁴. The following domains were considered: (1) the randomization process, (2) deviations from intended interventions, (3) missing outcome data, (4) outcome measurement, (5) the selection of reported results, and (6) overall bias³⁴. Following the Cochrane Handbook for Systematic Reviews of Interventions, the risk of bias was assessed by two independent reviewers²⁷. Disagreements between the reviewers were resolved through discussion and consultation with a third reviewer. **Statistical analysis.** Statistical analyses were performed using RevMan 5.3 software, which is provided by the Cochrane Collaboration (https://training.cochrane.org/online-learning/core-software-cochrane-reviews/ revman/revman-5-download). Continuous data were extracted as changes from baseline measurements. For studies not reporting SDs, the authors were contacted for raw data or, if unavailable, the data were estimated by calculating correlation coefficients in accordance with the instructions provided in the Cochrane Handbook for Systematic Reviews of Interventions²⁷. Results with P < 0.05 were considered statistically significant. We used the I^2 test to objectively measure statistical heterogeneity, with $I^2 \ge 75\%$ indicating considerable heterogeneity. Continuous variables are presented as standardized mean differences (SMDs) with 95% confidence intervals (CIs). The analysis was performed on the basis of different gel contents (corticosteroid, NSAID, herbal gel, or other gel). The meta-analysis was conducted only when at least two RCTs assessed the same gel type. SMDs were used to examine the strength of the relationships between variables in a population; an SMD of < 0.2 was considered to indicate a trivial effect with no clinical meaningfulness; 0.2–0.5 indicated a small effect; 0.5–0.8 indicated a moderate effect; and > 0.8 indicated a large effect³⁶.

Sensitivity analysis was performed by excluding one or two studies at a time to examine the stability and reliability of the meta-analysis. We performed this analysis to evaluate the effect of outliers²⁷. Articles with a high risk of bias or those reporting dubious results were regarded as outliers. Outliers were identified by the extent to which their removal reduced overall heterogeneity. Furthermore, we identified the probable causes of outliers after performing the sensitivity analysis.

A funnel plot was constructed to examine publication bias if the number of studies included in each analysis was more than 10.

Results

Search results. By using the search terms mentioned in the supplementary appendix, we initially retrieved 2176 studies. Of these, 633 duplicates were excluded using EndNote X9³⁷. Furthermore, 1491 studies that did not meet the inclusion criteria were excluded upon screening of their titles and abstracts. We screened the full texts of the remaining 52 papers and determined that 4 studies included duplicate study populations, 9 were not yet published, 2 did not compare the intervention with placebo gel, 21 did not examine phonophoresis, 1 had an additional intervention to the experimental intervention, 2 were not peer-reviewed articles, 2 compared phonophoresis with iontophoresis, and 2 did not mention SDs. Finally, nine articles were included in the meta-analysis^{38–46}. A PRISMA flowchart illustrates the selection process and the number of articles, with reasons included for why studies were excluded at each step of the meta-analysis⁴⁷ (Fig. 1).

Study characteristics. The selected studies included 222 and 201 patients in the intervention and control groups, respectively. All the selected RCTs were randomized, placebo-controlled trials³⁸⁻⁴⁶. Two studies used a corticosteroid gel^{38,41}, six used an NSAID gel^{40,42-46}, and one used a herbal gel³⁹. One study had a 1-month follow-up period⁴⁰, and one study had a 3-month follow-up period;⁴² other studies obtained follow-up data within 1 week after the intervention^{38,39,41,43-46}. Table 1 lists the main characteristics of the nine RCTs.

Risk-of-bias assessment. Figure 2 illustrates the risk of bias for each study. Nine studies had low risk associated with the randomization process^{38–46}. Six studies exhibited some concerns regarding the risk associated with deviations from the intended intervention^{40–42,44–46}, whereas three studies exhibited low risk^{38,39,43}. All nine studies had low risk related to missing outcome data^{38–46}. Regarding outcome measurements, five studies exhibited low risk^{38,39,41,43,44}, and four exhibited some concerns^{40,42,45,46}. Regarding the selection of reported results, all nine studies had low risk^{38–46}. The overall risk of bias was low for three studies^{38,39,43} and uncertain for six studies^{40–42,44–46}.

Pain scores. Pain scores were assessed in five studies where patients were treated with NSAID gel^{40,42-44,46}. These studies included 145 patients in the experimental group and 125 patients in the control group. In the analysis, SMD = -0.53, 95% CI [-1.02, -0.05], and $I^2 = 73\%$, which indicated a significant difference and favored the intervention group (Fig. 3).

Additionally, pain scores were assessed in two studies where patients were treated with corticosteroid gel^{38,41}. These studies included 42 patients in the experimental group and 41 patients in the control group. In the analysis, SMD = -0.53, 95% CI [-1.13, 0.07], and $I^2 = 46\%$, which indicated no significant difference between groups (Fig. 3).

WOMAC function scores. WOMAC function scores were assessed in five studies where patients were treated with NSAID gel^{40,42,44-46}. These studies included 137 patients in the experimental group and 117 patients in the control group. In the analysis, SMD = -0.75, 95% CI [-1.63, 0.13], I^2 = 90%, which indicated no significant difference between groups (Fig. 4).

WOMAC function scores were assessed in two studies where patients were treated with corticosteroid gel^{38,41}. These studies included 42 patients in the experimental group and 41 patients in the control group. In the analysis, SMD = -0.96, 95% CI [-1.47, -0.44], and $l^2 = 20\%$, which indicated a significant difference and favored the intervention group (Fig. 4).

Range of motion. The range of motion was assessed in three studies where patients were treated with NSAID gel^{40,45,46}. These studies included 84 patients in the experimental group and 64 patients in the control




Figure 1. Flowchart of article selection.

group. In the analysis, SMD = 1.07, 95% CI [-0.09, 2.00], and $I^2 = 90\%$, which indicated no significant difference between groups (Fig. 5). No study assessed the range of motion when corticosteroid gel was applied.

Walk tests. Walk tests were adopted in three studies where patients were treated with NSAID gel^{44–46}. These studies included 78 patients in the experimental group and 78 patients in the control group. In the analysis, SMD = -0.57, 95% CI [-1.27, 0.12], and $l^2 = 76\%$, which indicated no significant difference between groups (Fig. 6).

Only one study evaluated the effect of herbal gel. The study was not included in the meta-analysis because only one RCT was conducted³⁹. This study included 20 patients in the experimental group and 20 patients in the control group and focused on pain scores and walk test results. The herbal gel had a larger effect in the intervention group than in the control group in both tests.

Sensitivity analysis. In the sensitivity analysis, we observed that pain scores with NSAID gel were affected by the removal of studies. However, the effect of NSAID gel on range of motion became significant and favored the intervention group after one article was removed. All results indicated lower heterogeneity after articles were removed ($I^2 < 75\%$; Table 2).

Adverse events. Of the nine selected RCTs, four reported adverse effects^{39,40,43,46}. No adverse events were observed in these studies, indicating that participants tolerated the interventions well.

| | Therapeutic | Inte | rvention group | | Con | trol group | | | | |
|--|---|---------------------------|----------------|--------------------|-----|----------------------------|----------------|------------------|--|--|
| Author, year | ultrasound (mode; frequency; intensity; duration) | n Age in years, mean (SD) | | Content of gel | n | Age in years, mean (SD) | Content of gel | Follow up period | Outcome | |
| Ahmed et al., 2019 ³⁸ | Continuous; 1 MHz; 1 W/cm ² ; 10 min | 23 | 53.09 (5.46) | Dexamethasone | 23 | 50.59 (6.77) | Placebo | 1 week | Pain score and WOMAC function score | |
| Pinkaew et al., 2019 ³⁹ | Continuous; 1 MHz; 1 W/cm ² ; 10 min | 20 | 65.20 (8.34) | Phyllanthus amarus | 20 | 64.30 (9.71) | Placebo | 1 week | Pain score and 6-min walk test | |
| Zhao et al., 2015 ⁴⁰ | –; 40 kHz; 5000 Pa; – | 39 | 59.4 (8.9) | Diclofenac | 19 | 60.8 (9.0) | Placebo | 1 month | Pain score, WOMAC function score, and range of motion | |
| Oktayoğlu et al., 2014 ⁴² | Continuous; 1 MHz; 1.5 W/cm ² ; 10 min | 20 | 54.55 (8.65) | Diclofenac | 20 | 55.05 (10.08) | Placebo | 3 months | Pain score and WOMAC function score | |
| Toopchizadeh et al., 2014 ⁴¹ | -; -; 1.5 W/cm²; 5 min | 19 | 54.6 (6.23) | Dexamethasone | 18 | 56.95 (7.33) | Placebo | 1 week | Pain score, WOMAC function score, and timed up-and-go test | |
| Boyaci et al., 2013 ⁴⁴ | Continuous; 1 MHz; 1.5 W/cm ² ; 8 min | 33 | 52.45 (4.80) | Ketoprofen | 33 | 52.58 (7.27) | Placebo | 1 week | Pain score, WOMAC function score, 15-min walk- ing time | |
| Luksurapan et al., 2013 ⁴³ | Continuous; 1 MHz; 1 W/cm ² ; 10 min | 23 | 59.83 (9.88) | Piroxicam | 23 | 58.00 (11.22) | Placebo | 1 week | Pain score and WOMAC function score | |
| Akinbo et al., 2011 ⁴⁵ | Continuous; 1 MHz; 1 W/cm ² ; – | 15 | 64.29 (19.83) | Diclofenac | 15 | 64.92 (10.52) | Placebo | 1 week | WOMAC function score, range of motion, and 20-min walking time | |
| Kozanoglu et al., 2003 ⁴⁶ | Continuous; 1 MHz; 1 W/cm²; 5 min | 30 | 60.3 (9.2) | Ibuprofen | 30 | 59.4 (8.9) | Placebo | 1 week | Pain score, WOMAC function score, 20-min walking time, and range of motion | |

Table 1. Characteristics of selected randomized controlled trials. WOMAC, the Western Ontario and McMaster Universities Arthritis Index; SD, standard deviation.

Discussion

Knee osteoarthritis is a degenerative joint cartilage condition^{1,2}. The common clinical symptoms of knee osteoarthritis include knee pain that is gradual in onset and worsens with activity, knee stiffness and swelling, pain after prolonged sitting or resting, and pain that worsens over time⁴. Topical anti-inflammatory drugs are an alternative treatment choice with fewer gastrointestinal complications relative to oral drugs¹⁶⁻¹⁸.

In phonophoresis, ultrasound is used to deliver therapeutic drugs through absorption and permeation of the skin²¹. Despite the wide usage of this treatment, supporting scientific evidence is insufficient, especially with regard to symptomatic knee osteoarthritis. Thus, we conducted this study to investigate the effect of phonophoresis on knee osteoarthritis symptoms. Our analysis revealed significant differences in pain scores that indicated phonophoresis with NSAID gel and significant differences in WOMAC function score that indicated phonophoresis with corticosteroid gel.

We examined the strength of the relationships between variables in a population by determining effect sizes. The results revealed that NSAID gel moderately affected pain scores and that corticosteroid gel greatly affected WOMAC function scores. The findings indicated that phonophoresis could clinically and meaningfully improve the patients' pain and functional performance. In addition, no study has compared the effects of phonophoresis with those of physical therapy or other types of medical treatments according to our electronic database research. Future studies can fill this research gap.

Therapeutic ultrasound is a deep-heating modality used in physical therapy⁴². According to Rao et al., in therapeutic ultrasound, a transducer converts electrical energy into ultrasound through the piezoelectric principle⁴⁸. Although the exact mechanism underlying its effect remains known, the effect may be composed of two components, namely thermal and nonthermal⁴⁹. In terms of the thermal effect, therapeutic ultrasound induces muscle relaxation and increases connective tissue extensibility and local blood flow, all of which lead to tissue regeneration and reduce inflammation^{42,49}. The nonthermal ultrasound effect is related to acoustic cavitation with resultant increases in cell permeability, which is a potential pain relief mechanism⁴⁹. Zhang et al. suggested that therapeutic ultrasound is beneficial for reducing knee pain and improving physical function in patients with knee osteoarthritis and can be a safe treatment option⁵⁰. Phonophoresis refers to the use of ultrasound to deliver therapeutic drugs by absorption and permeation through the skin²¹. The advantage of therapeutic ultrasound is that it may promote the transdermal penetration of therapeutic drugs^{43,46}. Moreover, this method is noninvasive and has minimal risk of the adverse effects associated with the systemic administration of anti-inflammatory drugs; it also combines the therapeutic effects of ultrasound and topical drugs⁴³. Phonophoresis accounts for up to 30% of physiotherapy visits in some medical centers⁴⁵.




Figure 2. Study quality assessment.

| | Ex | perimental | | Control | | | 1 | Std. Mean Difference | Std. Mean Difference | | |
|--|-------------------------|------------------------|-----------------------|-----------------|--------------------------------|----------|----------------|---|----------------------|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | | |
| 1.1.1 NSAID gel | | | | | | | | | | | |
| Boyaci, 2013 [44] | -2.78 | 3.32029 | 33 | -2.06 | 4.101827 | 33 | 21.6% | -0.19 [-0.67, 0.29] | | | |
| Kozanoglu, 2003 [46] | -1.56 | 1.53 | 30 | -1.5 | 1.59 | 30 | 21.1% | -0.04 [-0.54, 0.47] | -+- | | |
| Luksurapan, 2013 [43] | -4.7 | 1.96 | 23 | -2.857 | 2.122 | 23 | 19.2% | -0.89 [-1.50, -0.28] | | | |
| Oktayoğlu, 2014 [42] | -1.825 | 5.01379 | 20 | -0.65 | 3.63668 | 20 | 18.9% | -0.26 [-0.89, 0.36] | | | |
| Zhao, 2015 [40] | -4.04 | 2.940976 | 39 | 0.02 | 2.809739 | 19 | 19.2% | -1.38 [-1.99, -0.77] | _ _ | | |
| Subtotal (95% CI) | | | 145 | | | 125 | 100.0% | -0.53 [-1.02, -0.05] | \bullet | | |
| Heterogeneity: $Tau^2 = 0.22$ | 2; Chi² = 1 | 14.96, df = | 4 (P = | 0.005); I | ² = 73% | | | | | | |
| 5 / | 2; Chi ² = 1 | 14.96, df = | 4 (P = | 0.005); I | 2 = 73% | | | | | | |
| Heterogeneity: Tau ² = 0.22 1.1.2 Corticosteroid gel Ahmed, 2019 [38] | 2; Chi ² = 3 | 14.96, df = 3.00993 | 4 (P = | | ² = 73% 3.622849 | 23 | 51.8% | -0.82 [-1.43, -0.22] | | | |
| 1.1.2 Corticosteroid gel Ahmed, 2019 [38] | | | | | | 23 18 | 51.8% 48.2% | -0.82 [-1.43, -0.22] -0.21 [-0.86, 0.44] | | | |
| 1.1.2 Corticosteroid gel Ahmed, 2019 [38] Toopchizadeh, 2014 [41] | -4.086 | 3.00993 | 23 | -1.295 | 3.622849 | | | | | | |
| 1.1.2 Corticosteroid gel | -4.086 -2.88 | 3.00993 2.07 | 23 19 42 | -1.295 -2.45 | 3.622849 1.95 | 18 | 48.2% | -0.21 [-0.86, 0.44] | | | |
| 1.1.2 Corticosteroid gel Ahmed, 2019 [38] Toopchizadeh, 2014 [41] Subtotal (95% CI) | -4.086 -2.88 | 3.00993 2.07 | 23 19 42 | -1.295 -2.45 | 3.622849 1.95 | 18 | 48.2% | -0.21 [-0.86, 0.44] | | | |
| 1.1.2 Corticosteroid gel Ahmed, 2019 [38] Toopchizadeh, 2014 [41] Subtotal (95% CI) | -4.086 -2.88 | 3.00993 2.07 | 23 19 42 | -1.295 -2.45 | 3.622849 1.95 | 18 | 48.2% | -0.21 [-0.86, 0.44] | | | |
| 1.1.2 Corticosteroid gel Ahmed, 2019 [38] Toopchizadeh, 2014 [41] Subtotal (95% CI) | -4.086 -2.88 | 3.00993 2.07 | 23 19 42 | -1.295 -2.45 | 3.622849 1.95 | 18 | 48.2% | -0.21 [-0.86, 0.44] | | | |

Figure 3. Forest plot for changes from baseline determined using the pain scores. SD, standard deviation; CI, confidence interval.

Scientific Reports | (2022) 12:12877 |




Figure 4. Forest plot for changes from baseline determined using the Western Ontario and McMaster

Universities Arthritis Index (WOMAC) function scores. SD, standard deviation; CI, confidence interval.

| | Ex | perimenta | | Control | | | | Std. Mean Difference | Std. Mean Difference |
|----------------------|------|-----------|-------|---------|---------|-------|--------|----------------------|----------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| 3.1.1 NSAID gel | | | | | | | | | |
| Akinbo, 2011 [45] | 8 | 2.54 | 15 | 5.25 | 2.42 | 15 | 32.0% | 1.08 [0.31, 1.85] | |
| Kozanoglu, 2003 [46] | 4.5 | 8.3 | 30 | 3.5 | 4.8 | 30 | 34.8% | 0.15 [-0.36, 0.65] | + |
| Zhao, 2015 [40] | 48 | 21.48767 | 39 | 0.8 | 26.1075 | 19 | 33.2% | 2.02 [1.35, 2.69] | |
| Subtotal (95% CI) | | | 84 | | | 64 | 100.0% | 1.07 [-0.09, 2.22] | ◆ |

Favours [control] Favours [experimental]

0 Favours [experimental] Favours [control]

Figure 5. Forest plot for changes from baseline based on range of motion. SD, standard deviation; CI, confidence interval.

| | Experimental | | | Control | | | 2 | Std. Mean Difference | Std. Mean Difference |
|----------------------|--------------|---------|-------|---------|---------|-------|--------|----------------------|----------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| 4.1.1 NSAID gel | | | | | | | | | |
| Akinbo, 2011 [45] | -2.51 | 0.87 | 15 | -1.23 | 0.83 | 15 | 27.5% | -1.46 [-2.28, -0.65] | |
| Boyaci, 2013 [44] | -3.21 | 10.2509 | 33 | -2.64 | 8.53348 | 33 | 36.7% | -0.06 [-0.54, 0.42] | -+- |
| Kozanoglu, 2003 [46] | -3 | 3.1 | 30 | -1.9 | 2 | 30 | 35.9% | -0.42 [-0.93, 0.10] | |
| Subtotal (95% CI) | | | 78 | | | 78 | 100.0% | -0.57 [-1.27, 0.12] | ◆ |

Figure 6. Forest plot for improvement in walk test scores. SD, standard deviation; CI, confidence interval.

-4

| | Content of gel | Outlier(s) | SMD (95% CI) before sensitivity analysis | <i>I</i> ² before sensitivity analysis | SMD (95% CI) after sensitivity analysis | <i>I</i> ² after sensitivity analysis |
|----------------------|--------------------|--|---|---|--|--|
| Pain score | NSAID gel | Zhao et al., 2015 ⁴⁰ | <u>-0.53 (-1.02, -0.05)</u> | 73% | -0.32 (-0.67, 0.03) | 38% |
| | Corticosteroid gel | - | -0.53 (-1.13, 0.07) | 46% | - | - |
| WOMAC function score | NSAID gel | Zhao et a.l, 2015 ⁴⁰ Akinbo et al., 2011 ⁴⁵ | -0.75 (-1.63, 0.13) | | | |
| | 90% | 0.04 (-0.27, 0.35) | | | | |
| | 1% | | | | | |
| | Corticosteroid gel | - | <u>-0.96 (-1.47, -0.44)</u> | 20% | - | - |
| Range of motion | NSAID gel | Kozanoglu et al., 2003 ⁴⁶ | 1.07 (-0.09, 2.22) | 90% | 1.57 (0.65, 2.49) | 69% |
| | Corticosteroid gel | - | - | - | - | - |
| Walk test | NSAID gel | Akinbo et al., 2011 ⁴⁵ | -0.57 (-1.27, 0.12) | 76% | -0.23 (-0.58, 0.12) | 0% |

Table 2. Sensitivity analysis. Significant results are underlined. WOMAC, the Western Ontario and McMaster Universities Arthritis Index; SMD, standard mean difference; CI, confidence interval.

Recently, gels with different contents have been developed for phonophoresis. Corticosteroid and NSAID gels are commonly used. Among the included RCTs, two focused on corticosteroid gels^{38,41}, six focused on NSAID gels^{40,42–46}, and one focused on herbal gels³⁹. The two studies that used corticosteroid gels used dexamethasone gels^{38,41}. Among the six RCTs that focused on NSAID gels, three used diclofenac gels^{40,42–45}, one used the ibuprofen gel⁴⁶, one used the ketoprofen gel⁴⁴, and one used the piroxicam gel⁴³. The herbal gel used was the *Phyllanthus amarus* gel³⁹. Although each type of gel exerts anti-inflammatory effects, their chemical properties (e.g., their tissue permeability through ultrasound waves) differ, as reported by Akinbo et al.⁴⁵ In their literature review, Srbely et al. indicated that the depth of penetration of a drug depends on its mass (which is inversely proportional to its molecular weight)⁵¹. Molecular weight; thus, it has a low drug mass and high permeability when applied through ultrasound. The aforementioned reasons may explain why patients in the corticosteroid gel subgroup exhibited greater improvements in some outcomes than did those in the NSAID gel subgroup⁴⁵. Thus, the selection of drug for phonophoresis appears to be as crucial to treatment success as the selection of ultrasound parameters³⁸.

Byl et al. reported that diffusion of topically applied drugs through the skin can be enhanced by preheating the skin to increase the kinetic energy⁵². Among our included RCTs, three studies followed this approach^{41,45,46}. The application of heat before treatment may have affected the results of these studies. Our analysis indicated that the outcomes reported by the studies that applied preheating were inconsistent. Some studies reported improved outcomes, whereas others indicated no differences when compared with outcomes without preheating application. Therefore, the exact effects of preheating the skin should be investigated in the future.

We conducted a sensitivity analysis by excluding one or two studies at a time to examine the stability and reliability of the meta-analysis. According to the Cochrane Handbook for Systematic Reviews of Interventions, heterogeneity may arise due to the presence of one or two outlying studies with results that are in conflict with those of the remaining studies²⁷. If an obvious reason for the outlying result is apparent, the study might be removed with confidence²⁷. Both Akinbo et al. and Kozanoglu et al. applied heat to the treatment site before treatment^{45,46}. They followed the principle indicated by Byl et al.⁵² However, the application of heat may affect treatment outcomes. The findings of the three studies applying preheating might differ from those of the other included studies^{39,45,46}. This difference might explain the change in results in the sensitivity analysis.

In their systematic review and meta-analysis, Wu et al. examined the effectiveness and safety of various therapeutic ultrasound methods²⁶. In the subanalysis of phonophoresis, three RCTs were examined^{43,44,46}. The results revealed that the phonophoresis ultrasound group had lower pain scores (SMD = -0.41, 95% CI [-0.71, -0.10]) but demonstrated no significant difference in functional performance (assessed on the basis of WOMAC score; SMD = -0.16, 95% CI [-0.46, 0.14]). In recent years, more studies on phonophoresis have been conducted^{38–46}. We examined the effect of phonophoresis on patients with knee osteoarthritis. We focused on the outcomes of pain and functional performance and determined that phonophoresis effectively improved such outcome measures.

This systematic review and meta-analysis has several strengths. First, this is the first meta-analysis of RCTs investigating the effects of phonophoresis for different types of gels on patients with knee osteoarthritis. Second, our electronic database search indicates that several studies are ongoing in this field. Thus, the results of this study can serve as a reference for future studies. Third, multiple major databases were searched, without language restrictions, prior to the selection of RCTs. Fourth, the data and quality of the selected studies were examined by at least two reviewers through a group consensus approach.

Our study has several limitations that may limit the generalizability of our results. First, heterogeneity was moderate to high for some outcomes, possibly because of varying disease severity, symptom duration, patient characteristics, and treatment protocol. Thus, additional studies are required to establish a standardized treatment protocol. Second, different gel contents, such as lidocaine or capsaicin, that could be applied in the experimental group were not investigated. Furthermore, only one study focused on herbal gels and was not included in our meta-analysis, although it revealed a positive effect. Future studies should examine the effects of different gel contents. Third, some studies did not mention blinding to therapeutics and the blinding of patients or assessors. Hence, some concerns regarding the risk of bias may persist. Fourth, we observed that the pain scores with NSAID gel were affected by the removal of articles when conducting the sensitivity analysis. This might compromise the stability and reliability of the meta-analysis. Fifth, the included studies had short follow-up durations. Therefore, we could not analyze long-term outcomes. Fifth, the sample sizes in each study and the number of studies included for each outcome were different. Thus, the outcomes should be interpreted with caution. Additional high-quality large-scale RCTs with long-term follow-up periods are required to overcome these limitations.

Conclusion

This is the first meta-analysis of RCTs to investigate and provide adequate evidence for the effect of phonophoresis for different gel types on patients with knee osteoarthritis. Our findings indicated that phonophoresis improves pain and functional performance with a moderate to large effect size over a short-term follow-up with either corticosteroid or NSAID gel. Furthermore, no adverse events were reported in the selected studies. Phonophoresis can be an effective treatment option for patients with knee osteoarthritis. However, because of the limitations of this study, additional high-quality, large-scale RCTs with long follow-up periods are required to confirm the benefit and long-term effects of this intervention.

Received: 10 August 2021; Accepted: 4 July 2022 Published online: 27 July 2022

References

- Masiero, S. *et al.* The role of thermal balneotherapy in the treatment of obese patient with knee osteoarthritis. *Int. J. Biometeorol.* 62, 243–252. https://doi.org/10.1007/s00484-017-1445-7 (2018).
- Scanzello, C. R. & Goldring, S. R. The role of synovitis in osteoarthritis pathogenesis. Bone 51, 249–257. https://doi.org/10.1016/j. bone.2012.02.012 (2012).
- Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J. P. & Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33–42. https://doi.org/10.1038/nrrheum.2010.196 (2011).
- 4. Hsu, H. & Siwiec, R. M. StatPearls (StatPearls Publishing Copyright © 2021 (StatPearls Publishing LLC., 2021).
- Magnusson, K., Turkiewicz, A. & Englund, M. Nature vs nurture in knee osteoarthritis—The importance of age, sex and body mass index. Osteoarthr. Cartil. 27, 586–592. https://doi.org/10.1016/j.joca.2018.12.018 (2019).
- Li, J. S. *et al.* Weight loss changed gait kinematics in individuals with obesity and knee pain. *Gait Post.* 68, 461–465. https://doi. org/10.1016/j.gaitpost.2018.12.031 (2019).
- Martel-Pelletier, J. et al. A new decision tree for diagnosis of osteoarthritis in primary care: International consensus of experts. Aging Clin. Exp. Res. 31, 19–30. https://doi.org/10.1007/s40520-018-1077-8 (2019).
- Aweid, O., Haider, Z., Saed, A. & Kalairajah, Y. Treatment modalities for hip and knee osteoarthritis: A systematic review of safety. J. Orthop. Surg. (Hong Kong) 26, 2309499018808669. https://doi.org/10.1177/2309499018808669 (2018).
- 9. Jevsevar, D. S. Treatment of osteoarthritis of the knee: Evidence-based guideline, 2nd edition. JAAOS J. Am. Acad. Orthopaed. Surg. 21, 571–576 (2013).
- Fransen, M. et al. Exercise for osteoarthritis of the knee: A Cochrane systematic review. Br. J. Sports Med. 49, 1554–1557. https:// doi.org/10.1136/bjsports-2015-095424 (2015).
- Hammer, N. M., Bieler, T., Beyer, N. & Midtgaard, J. The impact of self-efficacy on physical activity maintenance in patients with hip osteoarthritis—A mixed methods study. *Disabil. Rehabil.* 38, 1691–1704. https://doi.org/10.3109/09638288.2015.1107642 (2016).
- Zhang, W. *et al.* OARSI recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthr. Cartil.* 18, 476–499. https://doi.org/10.1016/j.joca.2010.01.013 (2010).
- Jevsevar, D. S. et al. Mixed treatment comparisons for nonsurgical treatment of knee osteoarthritis: A network meta-analysis. JAAOS J. Am. Acad. Orthopaed. Surg. 26, 325–336. https://doi.org/10.5435/jaaos-d-17-00318 (2018).
- 14. da Costa, B. R. *et al.* Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: A network meta-analysis. *Lancet* **390**, e21–e33. https://doi.org/10.1016/s0140-6736(17)31744-0 (2017).
- Adatia, A., Rainsford, K. D. & Kean, W. F. Osteoarthritis of the knee and hip. Part II: Therapy with ibuprofen and a review of clinical trials. J. Pharm. Pharmacol. 64, 626–636. https://doi.org/10.1111/j.2042-7158.2012.01456.x (2012).
- Wolff, D. G., Christophersen, C., Brown, S. M. & Mulcahey, M. K. Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: A systematic review and meta-analysis. *Phys. Sportsmed.* https://doi.org/10.1080/00913847.2021.1886573 (2021).
- Derry, S., Conaghan, P., Da Silva, J. A., Wiffen, P. J. & Moore, R. A. Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst. Rev.* 4, Cd007400. https://doi.org/10.1002/14651858.CD007400.pub3 (2016).
- Rodriguez-Merchan, E. C. Topical therapies for knee osteoarthritis. Postgrad. Med. 130, 607–612. https://doi.org/10.1080/00325 481.2018.1505182 (2018).
- 19. Baker, K. G., Robertson, V. J. & Duck, F. A. A review of therapeutic ultrasound: Biophysical effects. *Phys. Ther.* 81, 1351–1358 (2001).
- 20. Aiyer, R. *et al.* Therapeutic ultrasound for chronic pain management in joints: A systematic review. *Pain Med.* **21**, 1437–1448. https://doi.org/10.1093/pm/pnz102 (2019).
- Souza, J., Meira, A., Volpato, N. M., Mayorga, P. & Gottfried, C. Effect of phonophoresis on skin permeation of commercial antiinflammatory gels: Sodium diclofenac and ketoprofen. *Ultrasound Med. Biol.* 39, 1623–1630. https://doi.org/10.1016/j.ultrasmedb io.2013.02.009 (2013).
- Yildiz, N. et al. Comparison of ultrasound and ketoprofen phonophoresis in the treatment of carpal tunnel syndrome. J. Back Musculoskelet. Rehabil. 24, 39–47. https://doi.org/10.3233/bmr-2011-0273 (2011).
- 23. Deshpande, M. M. & Patil, C. B. Heel pain and phonophoresis. J. Indian Med. Assoc. 108, 365 (2010).
- Ay, S., Doğan, S. K., Evcik, D. & Başer, O. C. Comparison the efficacy of phonophoresis and ultrasound therapy in myofascial pain syndrome. *Rheumatol. Int.* 31, 1203–1208. https://doi.org/10.1007/s00296-010-1419-0 (2011).
- Vlak, T. Comparative study of the efficacy of ultrasound and sonophoresis in the treatment of painful shouder syndrome. *Reuma*tizam 46, 5–11 (1999).
- Wu, Y. et al. Effects of therapeutic ultrasound for knee osteoarthritis: A systematic review and meta-analysis. Clin. Rehabil. 33, 1863–1875. https://doi.org/10.1177/0269215519866494 (2019).
- Higgins JPT TJ, C. J., Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. www.training.cochrane.org/handbook.
- Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 151, 264–269. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 (2009).
- Wewers, M. E. & Lowe, N. K. A critical review of visual analogue scales in the measurement of clinical phenomena. *Res. Nurs. Health* 13, 227–236. https://doi.org/10.1002/nur.4770130405 (1990).
- Gandek, B. Measurement properties of the Western Ontario and McMaster Universities Osteoarthritis Index: A systematic review. *Arthritis Care Res. (Hoboken)* 67, 216–229. https://doi.org/10.1002/acr.22415 (2015).
- Gajdosik, R. L. & Bohannon, R. W. Clinical measurement of range of motion. Review of goniometry emphasizing reliability and validity. *Phys. Ther.* 67, 1867–1872. https://doi.org/10.1093/ptj/67.12.1867 (1987).
- 32. Enright, P. L. The six-minute walk test. Respir Care 48, 783-785 (2003).
- Podsiadlo, D. & Richardson, S. The timed "Up & Go": A test of basic functional mobility for frail elderly persons. J. Am. Geriatr. Soc. 39, 142–148. https://doi.org/10.1111/j.1532-5415.1991.tb01616.x (1991).
- Higgins, J. P. T. et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928. https:// doi.org/10.1136/bmj.d5928 (2011).
- Melsen, W. G., Bootsma, M. C., Rovers, M. M. & Bonten, M. J. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. *Clin. Microbiol. Infect.* 20, 123–129. https://doi.org/10.1111/1469-0691.12494 (2014).
- 36. Cohen J. Statistical Power Analysis for the Behavioral Sciences 2nd ed. (Lawrence Erlbaum Associates Publication, 1988).
- 37. EndNote v. EndNote X9 (Clarivate P, P., 2013).
- Said Ahmed, M., Boles Saweeres, E., Abdelkader, N., Abdelmajeed, S. & Fares, A. Improved pain and function in knee osteoarthritis with dexamethasone phonophoresis: A randomized controlled trial. *Indian J. Orthopaed.* 53, 700–707. https://doi.org/10.4103/ ortho.IJOrtho_639_18 (2019).
- Pinkaew, D., Kiattisin, K., Wonglangka, K. & Awoot, P. Phonophoresis of Phyllanthus amarus nanoparticle gel improves functional capacity in individuals with knee osteoarthritis: A randomized controlled trial. J. Bodyw. Mov. Ther. https://doi.org/10.1016/j.jbmt. 2019.04.013 (2019).

- 40. Zhao, J. *et al.* Therapeutic effects of low-frequency phonophoresis with a Chinese herbal medicine versus sodium diclofenac for treatment of knee osteoarthritis: A double-blind, randomized, placebo-controlled clinical trial. *J. Tradit. Chin. Med. chung i tsa chih ying wen pan* **36**, 613–617. https://doi.org/10.1016/s0254-6272(16)30080-2 (2016).
- Toopchizadeh, V., Javadi, R. & Sadat, B. E. Therapeutic efficacy of dexamethasone phonophoresis on symptomatic knee osteoarthritis in elderly women. Int. J. Women's Health Reprod. Sci. 2, 168–177. https://doi.org/10.15296/ijwhr.2014.25 (2014).
- Oktayoglu, P. et al. Comparison of the efficacy of phonophoresis and conventional ultrasound therapy in patients with primary knee osteoarthritis. Erciyes tip dergisi 36, 11–18. https://doi.org/10.5152/etd.2013.64 (2014).
- Luksurapan, W. & Boonhong, J. Effects of phonophoresis of piroxicam and ultrasound on symptomatic knee osteoarthritis. Arch. Phys. Med. Rehabil. 94, 250–255. https://doi.org/10.1016/j.apmr.2012.09.025 (2013).
- Boyaci, A., Tutoglu, A., Boyaci, N., Aridici, R. & Koca, I. Comparison of the efficacy of ketoprofen phonophoresis, ultrasound, and short-wave diathermy in knee osteoarthritis. *Rheumatol. Int.* 33, 2811–2818. https://doi.org/10.1007/s00296-013-2815-z (2013).
- Akinbo, S., Owoeye, O. & Adesegun, S. Comparison of the therapeutic efficacy of diclofenac sodium and methyl salicylate phonophoresis in the management of knee osteoarthritis. *Turk. J. Rheumatol.* 26, 111–119. https://doi.org/10.5606/tjr.2011.017 (2011).
- 46. Kozanoglu, E., Basaran, S., Guzel, R. & Guler-Uysal, F. Short term efficacy of ibuprofen phonophoresis versus continuous ultrasound therapy in knee osteoarthritis. *Swiss Med. Wkly.* **133**, 333–338 (2003).
- Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71. https://doi. org/10.1136/bmj.n71 (2021).
- Rao, R. & Nanda, S. Sonophoresis: Recent advancements and future trends. J. Pharm. Pharmacol. 61, 689–705. https://doi.org/10. 1211/jpp.61.06.0001 (2009).
- 49. Robertson, V. J. & Baker, K. G. A review of therapeutic ultrasound: Effectiveness studies. Phys. Ther. 81, 1339–1350 (2001).
- Zhang, C. *et al.* Effects of therapeutic ultrasound on pain, physical functions and safety outcomes in patients with knee osteoarthritis: A systematic review and meta-analysis. *Clin. Rehabil.* **30**, 960–971. https://doi.org/10.1177/0269215515609415 (2016).
- 51. Srbely, J. Z. Ultrasound in the management of osteoarthritis: Part I: A review of the current literature. J. Can. Chiropr. Assoc. 52, 30–37 (2008).
- Byl, N. N. The use of ultrasound as an enhancer for transcutaneous drug delivery: Phonophoresis. *Phys. Ther.* 75, 539–553. https:// doi.org/10.1093/ptj/75.6.539 (1995).

Acknowledgements

This manuscript was edited by Wallace Academic Editing.

Author contributions

F.-A.Y. and H.-L.C. conceptualized and designed the study and drafted the manuscript. H.-C.C. critically revised the manuscript for intellectual content. C.-W.P., and T.-H.L. conducted a comprehensive search for articles that met the eligibility criteria. F.-A.Y. and H.-L.C. extracted the relevant data and assessed the quality of the selected trials. H.-C.C., R.E. and T.-H.L. provided statistical expertise, analyzed and interpreted the data, and submitted the manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-022-16084-8.

Correspondence and requests for materials should be addressed to H.-C.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022